An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine the drug characteristics of Ticagrelor, and to determine if 4 weeks treatment will reduce the blood clotting.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Clopidogrel; Ticagrelor

Criteria

Inclusion Criteria:

• Any Percutaneous Coronary Intervention, more than 3 months prior to randomization

• Previous documented acute coronary syndrome (ACS), more than 3 months prior to randomisation

• Treatment with ASA

Exclusion Criteria:

• ACS, transient ischemic attack (TIA), or Stroke within the 3 months prior to randomisation

• Known concurrent disease of stroke or TIA with atrial fibrillation

• Persons who are being treated with blood clotting agents that cannot be stopped